Nina Sanford: Unresectable HCC treated with IO+SBRT

Nina Sanford posted on X about recent paper by Chi Leung Chiang et al., titled “Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma” published on JAMA Oncology.

Authors: Chi Leung Chiang, Kenneth Sik Kwan Chan, Keith Wan Hang Chiu, Francis Ann Shing Lee, Wenqi Chen, Natalie Sean Man Wong, Ryan Lok Man Ho, Venus Wan Yan Lee, Kwan Man, Feng Ming Kong, Albert Chi Yan Chan.

“Unresectable HCC (median tumor diameter 10cm, 60% MVI) treated with IO+SBRT (N=63):

-46% achieved complete response, much higher than prior trials of IO alone: atezo/bev (CR 5.5% IMBRAVE150) and STRIDE (3.3% CR)
-CR associated with better OS (3yr 76% vs. 28%)!

Other points:
-Interestingly the median dose was 35 Gy in 5 fractions: HCC is radiosensitive & may not need ablative dosing, particularly when combined w IO.
-TACE allowed (78% received pre-SBRT)
-Upcoming RCT NRG GI012 will assess atezo/bev +/- SBRT.”

Source: Nina Sanford/X

Dr. Nina Niu Sanford is an Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital. She specializes in treating gastrointestinal cancers and actively participates in clinical trials combining high-dose radiation therapy with immunotherapy. Additionally, she researches healthcare access disparities and conducts pan-cancer outcomes research using large databases.